# Day One Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/day-one-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.dayonebio.com
- Total disclosed funding: $190M
- Latest round: Series B (Feb 1, 2021)
- Investors on record: 11

## About

Based in California, US, and founded in 2018, Day One Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes targeted therapies for patients of all ages with genomically defined cancers. In March 2026, Servier agreed to fully acquire Day One Biopharmaceuticals, Inc. from Access Industries, Atlas Venture, Canaan Partners, Boxer Capital, BVF Partners, Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, RA Capital Management, T. Rowe Price, and Viking Global Investors for USD 21.50 per share, or approximately USD 2.5 billion in equity value. The company trades in the NASDAQ-GS stock exchange under the ticker symbol DAWN. In addition, Day One Biopharmaceuticals employs 29 full-time employees.

Day One Biopharmaceuticals offers accelerating medicines, DAY101, and Pimasertib to the patients. DAY101 is an oral and highly selective investigational pan-RAF inhibitor, which is under clinical development for the treatment of patients with relapsed or progressive low-grade glioma, or pLGG. Pimasertib is an oral, small-molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), of the MAPK signaling pathway. In addition, the company develops new insights from the biology of pediatric cancer and new therapies that meet the critical needs of people of all ages living with cancer, starting from the biology of childhood cancer, helping patients and doctors deal with cancer.

Day One Biopharmaceuticals, Inc. plans to use its proceeds from February 2021 funding to accelerate and expand its search and evaluation capabilities, support drug development efforts, and continue advancing commercial launch plans for the company’s lead program, DAY101.

## Funding rounds

- Series B, Feb 1, 2021, $130M — Atlas Venture, T Rowe Price, Canaan Partners, Access Industries, Viking Global Investors, BVF Partners, RA Capital Management, Franklin Templeton, Perceptive Advisors, Boxer Capital, Janus Henderson Investors
- Series A, May 21, 2020, $60M — Atlas Venture, Canaan Partners, Access Industries

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Janus Henderson Investors — Series B